Management, Pipeline Make Tesaro (TSRO) an Attractive Speculative Play - Cramer
Tweet Send to a FriendGet Alerts TSRO Hot Sheet
Price: $35.91 +0.08%
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade TSRO Now!
Tesaro (Nasdaq: TSRO) shares are higher amid a positive mention by famed stock picker Jim Cramer late last week.
According to Cramer, Tesaro has become his favorite speculative biotech stock. Though the company hasn't been public very long, Cramer noted the strong management behind the firm, folks with a history of building and selling companies.
Tesaro focuses primarily on improving the lives of cancer patients. It's first dug -- Rolapitant -- was licensed from Opko Health (NYSE: OPK) for a grat price and the drug is now in Phase III testing. Rolapitant helps to prevent chemo patients from experiencing nausea during treatment.
Two other drugs Tesaro currently has in development include one that attacks tumors directly and the other aiming to treat specific lung cancers.
Cramer notes that Tesaro has about $138 million in cash with no debt on the books. Those sort of numbers and its robust pipeline make Tesaro a stock that could easily trade for well above its current range.
Shares are up 5.6 percent on the session and up about 18 percent from its IPO price of $13.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
According to Cramer, Tesaro has become his favorite speculative biotech stock. Though the company hasn't been public very long, Cramer noted the strong management behind the firm, folks with a history of building and selling companies.
Tesaro focuses primarily on improving the lives of cancer patients. It's first dug -- Rolapitant -- was licensed from Opko Health (NYSE: OPK) for a grat price and the drug is now in Phase III testing. Rolapitant helps to prevent chemo patients from experiencing nausea during treatment.
Two other drugs Tesaro currently has in development include one that attacks tumors directly and the other aiming to treat specific lung cancers.
Cramer notes that Tesaro has about $138 million in cash with no debt on the books. Those sort of numbers and its robust pipeline make Tesaro a stock that could easily trade for well above its current range.
Shares are up 5.6 percent on the session and up about 18 percent from its IPO price of $13.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17
- Pier 1 Imports (PIR) Sets Sights on Growing Ecommerce
- SolarCity (SCTY) is 'Hot, Hot, Hot', But Questions About Financing Deal Raised
Create E-mail Alert Related Categories
Analyst Comments, Insiders' BlogRelated Entities
Jim Cramer
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
